Celltrion, Inc. (KRX:068270)
South Korea · Delayed Price · Currency is KRW | Market Cap | 37.60T +11.6% |
| Revenue (ttm) | 4.16T +17.0% |
| Net Income | 1.03T +143.6% |
| EPS | 4,660.00 +148.4% |
| Shares Out | 209.59M |
| PE Ratio | 38.50 |
| Forward PE | 28.75 |
| Dividend | 750.00 (0.41%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 772,870 |
| Average Volume | 657,044 |
| Open | 182,000 |
| Previous Close | 179,400 |
| Day's Range | 182,000 - 191,400 |
| 52-Week Range | 144,615 - 251,000 |
| Beta | 0.39 |
| RSI | 44.65 |
| Earnings Date | May 4, 2026 |
About Celltrion
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and u... [Read more]
Financial Performance
In 2025, Celltrion's revenue was 4.16 trillion, an increase of 17.01% compared to the previous year's 3.56 trillion. Earnings were 1.03 trillion, an increase of 143.58%.
Financial StatementsNews
Celltrion Acquires Gifrer to Expand EU Operations
Celltrion Acquires Gifrer to Expand EU Operations
Celltrion Slides: Q1 2026
Celltrion has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Celltrion Q1 Net Income Rises
(RTTNews) - Celltrion (068270.KS) reported first quarter net income attributable to shareholders of the parent company of 346.14 billion Korean won, an increase of 218.54% year-over-year from 108.67 b...
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA ® (infliximab-dy...
Celltrion Enters Contract Manufacturing Agreement With Global Pharmaceutical Company
(RTTNews) - Celltrion (068270.KS) has signed a contract manufacturing agreement with a global pharmaceutical company for the supply of drug substance. Celltrion will supply drug substance for three ye...
Celltrion Announces Commercial Availability In US Of AVTOZMA SC, Tocilizumab Biosimilar
(RTTNews) - South Korean biopharmaceutical company Celltrion, Inc. (068270.KS) announced Monday that AVTOZMA (tocilizumab-anoh) subcutaneous (SC) formulation is now commercially available to patients ...
Celltrion Annual report: Q4 2025
Celltrion has published its Q4 2025 annual report on March 16, 2026.
Celltrion Slides: Q4 2025
Celltrion has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 16, 2026.
Celltrion Reports Post-hoc Analysis From LIBERTY Studies
(RTTNews) - Celltrion (068270.KS) announced new data from a post-hoc analysis of the LIBERTY studies, showing that subcutaneous infliximab restored and maintained response in most Crohn's disease and ...
FDA Clears New Prefilled Syringe Of Celltrion's OMLYCLO, Interchangeable Biosimilar To XOLAIR
(RTTNews) - Celltrion Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO (omalizumab-igec)—the first and only biosimilar designated as interchan...
Celltrion Slides: Q3 2025
Celltrion has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 4, 2025.
FDA Approves Celltrion's EYDENZELT, Biosimilar To EYLEA, For Multiple Retinal Conditions
(RTTNews) - Celltrion Inc. announced that the U.S. Food and Drug Administration approved EYDENZELT (aflibercept-boav), biosimilar referencing EYLEA (aflibercept), for the treatment of neovascular (wet...
Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal
Asian drug stocks faced a downturn. This followed US President Trump's tariff threat on imported pharmaceuticals. South Korean and Japanese drugmakers experienced declines. Samsung Biologics and Sumit...
Celltrion (CONI.F) Acquires Imclone Systems to Strengthen U.S. Presence
Celltrion (CONI.F) Acquires Imclone Systems to Strengthen U.S. Presence
Celltrion Slides: Q2 2025
Celltrion has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 6, 2025.
Celltrion to Cancel $72 Million in Shares to Boost Shareholder Value
Celltrion to Cancel $72 Million in Shares to Boost Shareholder Value
Celltrion Slides: Q1 2025
Celltrion has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on May 9, 2025.
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing ...
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager | ABP Stock News
Shilpa Medicare settles Celltrion arbitration case with $3.4 million agreement
Shilpa Medicare Limited has entered into a settlement agreement with Celltrion Inc., a South Korea-based pharmaceutical company, thereby resolving an ongoing arbitration dispute. The company informed ...
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
Remdantry™ (previously known as Inflectra®), developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar infliximab in Canada and will be commercially available across Canada ...
Celltrion Quarterly report: Q4 2024
Celltrion has published its Q4 2024 quarterly earnings report on March 16, 2025.
Celltrion Slides: Q4 2024
Celltrion has posted slides in relation to its Q4 2024 quarterly earnings report, which was published on March 16, 2025.
Celltrion Annual report: Q4 2024
Celltrion has published its Q4 2024 annual report on March 16, 2025.
Celltrion’s Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian mark...
Celltrion Quarterly report: Q3 2024
Celltrion has published its Q3 2024 quarterly earnings report on January 17, 2025.